KRAS mutant and RAS/BRAF wild type colorectal cancer cells exhibit differences in the rewiring of signal transduction that can impact on future therapeutic strategies
Year: 2018
Type: article
Abstract: Background: KRAS mutant (KRAS MT) and RAS/BRAF wild type (RAS WT) colorectal cancer (CRC) responds differently to targeted agents. A better understanding of early effects on signal transduction following exposure to targeted agents may explain this and inform future therapeutic strategies.
Source: Annals of Oncology
Authors: A. Georgiou, A. Stewart, P. Thavasu, E.A. Coker, S. Poelsterl, B. Al-Lazikani, D. Cunningham, S. Whittaker, U. Banerji
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $5,080
OpenAlex ID: W2896293186